Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDC00111

Target Information
NameB2 bradykinin receptor    
Type of targetClinical trial target    
BK B(2) receptor    
BK-2 receptor    
Bradykinin B2 receptor    
DiseaseAlzheimer's disease
[ICD9: 331.0   ICD10: G30]
[ICD9: 338   ICD10: R52]
[ICD9: 710-719   ICD10: M00-M25]
[ICD9: 493   ICD10: J45]
Brain Cancer
[ICD9: 191   ICD10: C71]
Cardiac hypertrophy
[ICD9: 429.3   ICD10: I51.7]
Cardiovascular disease, unspecified
[ICD9: 390-459   ICD10: I00-I99]
Cerebral edema
[ICD9: 348.5   ICD10: G93.6]
Chronic rhinitis
[ICD9: 472.0, 477   ICD10: J00, J30, J31.0]
[ICD9: 556.9   ICD10: K50-K52]
Diabetic disorders
[ICD9: 250   ICD10: E08-E13]
Diabetic nephropathy
[ICD9: 250.4   ICD10: E10.2, E11.2, E13.2]
Hepatorenal syndrome[1]
Hereditary Angioedema (HAE)
[ICD9: 277.6   ICD10: D84.1]
[ICD9: 401   ICD10: I10, I11, I12, I13, I15]
Liver Disease
[ICD9: 570-574   ICD10: K70-K77]
Lung cancer
[ICD9: 162   ICD10: C33-C34]
Myocardial infarction
[ICD9: 410   ICD10: I21, I22]
[ICD9: 577.0-577.1   ICD10: K85, K86.0K86.1]
[ICD9: 995.91   ICD10: A40, A41]
Tissue injury[1]
Traumatic brain injuries
[ICD9: 800, 801, 803, 804, 850-854   ICD10: S06]
Visceral pain
[ICD9: 338,780   ICD10: R52, G89]
Drug(s)IcatibantPhase III, Positive phase III resultsHereditary Angioedema (HAE)[6][7][8]
IcatibantPhase IIa completedLiver Disease[6][7][8]
AnatibantPhase IITraumatic Brain Injuries[9][10]
LabradimilDiscontinuedBrain Cancer, Pediatric[3][4]
BioChemical ClassG-protein coupled receptor (rhodopsin family)    
PathwayCalcium signaling pathway
Complement and coagulation cascades
Neuroactive ligand-receptor interaction
Regulation of actin cytoskeleton
UniProt IDP30411
FunctionReceptor for bradykinin. It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system.    
Related US Patent6,479,515
Target ValidationClick to Find Target Validation Information.    
Inhibitor (D)Arg-Arg-Pro-Hyp-Gly-Phe-Ser-[11]
H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH (JMV1638)[12]
H-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH (JMV1431)[12]
H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH (JMV1645)[12]
H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH (JMV1669)[12]
Quinapril analogue[15]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Bradykinin B2 receptor as a potential therapeutic target. Drug News Perspect. 2000 May;13(4):213-25. To Reference
Ref 2Kallikrein-kinin system in acute pancreatitis: potential of B(2)-bradykinin antagonists and kallikrein inhibitors. Pharmacology. 2000 Apr;60(3):113-20. To Reference
Ref 3Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J Transl Med. 2009 May 13;7:33. To Reference
Ref 4Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity. Brain Res. 2002 Nov 29;956(2):211-20. To Reference
Ref 5Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation. Can J Physiol Pharmacol. 2002 Apr;80(4):328-33. To Reference
Ref 6Bradykinin receptor antagonists--a review of the patent literature 2005-2008. Expert Opin Ther Pat. 2009 Jul;19(7):919-41. To Reference
Ref 7Pharmacological characterization of the bradykinin B2 receptor antagonist MEN16132 in rat in vitro bioassays. Eur J Pharmacol. 2009 Aug 1;615(1-3):10-6. Epub 2009 May 13. To Reference
Ref 8Bradykinin in the heart: friend or foe? Circulation. 1999 Dec 7;100(23):2305-7. To Reference
Ref 9Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome. Crit Care Med. 2009 Jul;37(7):2228-34. To Reference
Ref 10Anatibant, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury. Neurosci Lett. 2009 Apr 24;454(2):115-7. Epub 2009 Feb 11. To Reference
Ref 11J Med Chem. 1991 Mar;34(3):1230-3.Design and conformational analysis of several highly potent bradykinin receptor antagonists. To Reference
Ref 12J Med Chem. 2000 Jun 15;43(12):2382-6.Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. To Reference
Ref 13J Med Chem. 2009 Jul 23;52(14):4370-9.Novel small molecule bradykinin B2 receptor antagonists. To Reference
Ref 14J Med Chem. 2008 Nov 27;51(22):7094-8.cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. To Reference
Ref 15Bioorg. Med. Chem. Lett. 5(4):367-370 (1995) To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543